• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Medpace to undergo equity recapitilization

Medpace to undergo equity recapitilization

May 24, 2011
CenterWatch Staff

US-based CRO Medpace will undergo an “equity recapitalization” with affiliates of CCMP Capital Advisors, under which CCMP will end up with an 80% stake in the company while the remaining 20% share will belong to the current Medpace management team, according to Pharma Times.

No financial details were released.

The existing Medpace management will remain in place, as will August Troendle as president and chief executive officer. Medpace will also continue to operate out of Cincinnati, Ohio once the recapitalization is completed.

Medpace’s relationship with CCMP will allow the CRO to “add global operational depth” and to further its reputation as “a company well-known for therapeutic and operational excellence” in conducting phase I-IV clinical studies.

“The transaction will provide resources to make the strategic long-term investments that are needed to advance our leadership position, grow the core business, and expand our global reach,” commented Troendle. 

Medpace has more than 1,000 employees and clinical trial experience in over 40 countries.

As well as phase II-IV development services, the CRO provides phase I/ IIA clinical services through Medpace Clinical Pharmacology; central laboratory and therapeutically specialized testing through Medpace Reference Laboratories; bioanalytical services through Medpace Bioanalytical Laboratories; centralized imaging core laboratory management and reading through Imagepace; and medical device development through Medpace Medical Device.

.

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing